Safety and efficacy of anti-PD1 therapy for metastatic melanoma and non-small cell lung cancer in patients with concurrent viral hepatitis

被引：0
|
作者：
Kothapalli, A. [1 ]
Khattak, M. [2 ]
机构：
[1] Fiona Stanley Hosp, Dermatol, Perth, WA, Australia
[2] Fiona Stanley Hosp, Med Oncol, Perth, WA, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2018年 / 59卷
关键词：
PEMBROLIZUMAB; IPILIMUMAB;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [21] The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations
    Chen, Lu
    Xie, Jingyuan
    Zhu, Meiying
    Wang, Dong
    Liu, Hongbin
    Zhan, Ping
    Yin, Jie
    Ye, Mingxiang
    Song, Yong
    Lv, Tangfeng
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (01) : 137 - 149
  • [22] Neutrophil/Lyrnphocyte Ratio in Advanced Non-Small Cell Lung Cancer: Correlation with Prognosis and Response to Anti-PD1 Therapy
    Galata, Domenico
    Logroscino, Antonio Fabio
    Misino, Andrea
    Montagna, Elisabetta Sara
    Petrillo, Patrizia
    Ricci, Donata
    Catino, Annamaria
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1329 - S1330
  • [23] Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer
    Hu, Haoyue
    Min, Min
    Dai, Hongchun
    Tang, Youpan
    He, Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2025, 18 (01): : 37 - 41
  • [24] Comparison of iRECIST to RECIST1.1 for Following Response to Anti-PD1 Therapy in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Katz, S.
    Hammer, M.
    Bagley, S.
    Aggarwal, C.
    Bauml, J.
    Nachiappan, A.
    Simone, C.
    Langer, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1551 - S1551
  • [25] Non-small cell lung cancer therapy: safety and efficacy in the elderly
    Glotzer, Owen S.
    Fabian, Thomas
    Chandra, Anurag
    Bakhos, Charles T.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2013, 5 : 113 - 121
  • [26] The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
    Tanvetyanon, Tawee
    Creelan, Benjamin C.
    Antonia, Scott J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 903 - 910
  • [27] EFFICACY AND OUTCOME OF ANTI-PD1 THERAPY IN PATIENTS WITH LUNG CANCER BRAIN METASTASIS
    Thapa, Bicky
    Shah, Bhavan
    Lauko, Adam
    Ahluwalia, Manmeet
    NEURO-ONCOLOGY, 2017, 19 : 39 - 39
  • [28] The Efficacy and Safety of Anti-PD-1 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Systematic Review
    Di, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1917 - S1917
  • [29] ANTI-PD1 THERAPY IN PATIENTS WITH METASTATIC MELANOMA: A SINGLE CENTRE EXPERIENCE
    Nguyen, B.
    Robinson, E.
    Arora, A.
    Sayed, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 65 - 65
  • [30] INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
    Yam, A. O.
    Mersiadis, A.
    Gao, B.
    Hui, R.
    Nagrial, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 72
12345